| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-06-05 | nintedanib | mesothelioma | 3 | Boehringer Ingelheim (Germany) | Cancer - Oncology - Rare diseases |
| 2017-06-05 | plazomicin | complicated urinary tract infections (cUTI) | Achaogen (USA - CA) | Infectious diseases | |
| 2017-06-05 | plazomicin | infections due to carbapenem-resistant enterobacteriaceae (CRE) | 3 | Achaogen (USA - CA) | Infectious diseases |
| 2017-06-05 | enfortumab vedotin (ASG-22ME) | previously treated metastatic urothelial cancer | 1 | Seattle Genetics (USA - WA), a wholly owned subsidiary of Takeda Pharmaceutical (Japan) Agensys, an affiliate of Astellas (Japan) | Cancer - Oncology |
| 2017-06-05 | SPEAR® T-Cell Therapy Targeting NY-ESO-1 | recurrent epithelial ovarian, primary peritoneal or fallopian tube carcinoma with refractory or platinum-resistant disease expressing NY-ESO-1 | 1-2 | Adaptimmune (UK) | Cancer - Oncology |
| 2017-06-05 | NY-ESOc259T cell therapy product | synovial sarcoma | 1-2 | Adaptimmune (UK) | Cancer Oncology |
| 2017-06-05 | NKTR-214 | solid tumors including melanoma, renal cell carcinoma (RCC), bladder cancer, colorectal cancer | 1-2 | Nektar Therapeutics (USA - CA) | Cancer - Oncology |
| 2017-06-05 | [Zr-89]-HuMab-5B1 (MVT-5873) | pancreatic cancer - locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) or other CA19-9 positive malignancies | 1 | MabVax Therapeutics (USA - CA) | Cancer - Oncology |
| 2017-06-05 | NY-ESO1c259T cell therapy product | non-small cell lung cancer (NSCLC) | 1-2 | Adaptimmune (UK) | Cancer - Oncology |
| 2017-06-05 | RX-P2177 | gonorrhea | preclinical | Melinta Therapeutics (USA - CT) | Infectious diseases |
| 2017-06-05 | pracinostat | acute myeloid leukemia | 2 | Mei Pharma (USA - CA) Helsinn Group (Switzerland) | Cancer - Oncology |
| 2017-06-05 | fruquintinib | locally advanced or metastatic colorectal cancer | 3 | Hutchison China MediTech Limited "ChiMed" (China) | Cancer - Oncology |
| 2017-06-05 | NY-ESO SPEAR® T-cell therapy | myxoid round cell liposarcoma | 1 | Adaptimmune (UK) | Cancer - Oncology |
| 2017-06-05 | GMI-1271 | acute myeloid leukemia (AML) | 1-2 | GlycoMimetics (USA - Md) | Cancer - Oncology |
| 2017-06-04 | Lynparza™ (olaparib) | HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations | 3 | AstraZeneca (UK) | Cancer - Oncology |
| 2017-06-04 | elacestrant (RAD1901) | estrogen receptor positive (ER+) breast cancer | 1 | Radius Health (USA - MA) | Cancer - Oncology |
| 2017-06-04 | PRS-080 | anemia | 1 | Pieris (Germany) | Hematological diseases |
| 2017-06-04 | burtomab (131-I-8H9), now omburtamab | refractory leptomeningeal metastasis from neuroblastoma | Memorial Sloan Kettering Cancer Center (USA - NY) Y-mAbs Therapeutics (USA - NY) | Cancer - Oncology | |
| 2017-06-03 | abemaciclib (LY2835219) | HR+, HER2+ advanced breast cancer | 2 | Eli Lilly (USA - IN) | Cancer - Oncology |
| 2017-06-03 | AG-120 (ivosidenib) | cholangiocarcinoma | 1 | Agios Pharmaceuticals (USA -MA) | Cancer - Oncology - Rare diseases |
